Sinopharm CNBG Announces Pneumonia-Specific COVID-19 Drug
Sinopharm CNBG Announces Pneumonia-Specific COVID-19 Drug
BEIJING--September 20, 2021--Researched by Industrial Info Resources (Sugar Land, Texas)--Sinopharm China National Biotec Group (Sinopharm CNBG) recently announced the intravenous COVID-19 Human Immunoglobulin (pH4), which was developed by its subsidiary Tiantan Biological Company Limited, was approved for clinical trials by the Chinese National Medical Products Administration (NMPA).
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Mexico Registers US$2 Billion in Pharmaceutical Investments
- New England Sees $27 Billion in Projects Under Construction
- Pharma, Manufacturing Lead Indiana to $21.6 Billion of Projects Under Const...
- India Aims to Reduce Dependence on China for Pharma Market
- BMS Investing $400 Million in Dublin Sterile Drug Expansion